Clinical trial · Observational
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer
Patient Outcomes Following Interval and Delayed Cytoreductive Surgery in Advanced Ovarian Cancer: A GO SOAR Led Study (GO SOAR2)
NCT05523804CI-TRIAL-00060612GO SOAR2unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare patient outcomes following interval and delayed cytoreductive surgeries and no surgery (neoadjuvant chemotherapy alone) and international variations in access to cytoreductive surgeries in women with advanced stage ovarian cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| delayed cytoreductive surgery | Procedure | — | UNRESOLVED |
| interval cytoreductive surgery | Procedure | — | UNRESOLVED |
| no surgery | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- interval cytoreductive surgery
- description
- women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) cytoreductive surgery
- interventionNames
- Procedure: interval cytoreductive surgery
- label
- delayed cytoreductive surgery
- description
- women with stage III-IV ovarian cancer, undergoing delayed (\>5 cycles of chemotherapy) cytoreductive surgery
- interventionNames
- Procedure: delayed cytoreductive surgery
- label
- no surgery
- description
- women with stage III-IV ovarian cancer, undergoing \>5 cycles of chemotherapy alone (no cytoreductive surgery)
- interventionNames
- Other: no surgery
Primary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Women with stage III-IV ovarian cancer, undergoing interval (after 3-4 cycles of chemotherapy) or delayed (\>5 cycles of chemotherapy) cytoreductive surgeries or no cytoreductive surgery (\>5 cycles of chemotherapy alone. Exclusion Criteria: Women undergoing recurrent cytoreductive surgery.
References
Publications (1)
- DERIVEDGaba F, Ash K, Blyuss O, Bizzarri N, Kamfwa P, Ramirez PT, Kotsopoulos IC, Chandrasekaran D, Gomes N, Butler J, Nobbenhuis M, Ind T, Heath O, Barton D, Jeyarajah A, Brockbank E, Lawrence A, Dilley J, Manchanda R, Phadnis S, Soar GO. Patient outcomes following interval and delayed cytoreductive surgery in advanced ovarian cancer: protocol for a multicenter, international, cohort study (Global Gynaecological Oncology Surgical Outcomes Collaborative). Int J Gynecol Cancer. 2022 Dec 5;32(12):1606-1610. doi: 10.1136/ijgc-2022-004101. PMID 36379595